Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1968 results
September 2026
-
Story Access to Healthcare
Fortune includes Novartis in 2026 Change The World List for malaria program
For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.
-
Story People and Culture
The Day AI Made Me Rethink What Science Could Do
Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research
-
Statement
Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
-
Press release
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based… -
Story Discovery
American Chemical Society honors Novartis researchers
Novartis chemists receive “Heroes of Chemistry” honor from the American Chemical Society for work on CML drug discovery.
-
Story Access to Healthcare
25 years of expanding access to cancer care
For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.
-
Ad hoc release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-… -
Ad hoc release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not… -
Ad hoc release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with…
July 2026
-
Press release
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in… -
Story Discovery
Smarter decisions at scale: How Novartis is using AI to advance R&D
Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients